Symposia: Cellular Immunotherapies: Late Phase and Commercially Available Therapies
	
	
	Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, ALL, Lymphomas, Clinical Research, B Cell lymphoma, Plasma Cell Disorders, Diseases, real-world evidence, registries, Lymphoid Malignancies
	Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, ALL, Lymphomas, Clinical Research, B Cell lymphoma, Plasma Cell Disorders, Diseases, real-world evidence, registries, Lymphoid Malignancies
Monday, December 11, 2023: 4:30 PM-6:00 PM
	Room 6CF 
		(San Diego Convention Center)
	
	
	
	
	   
	
	
			
		Moderators:
			
				
				
					
						
						
						
							Krina K. Patel, MD, MSc, The University of Texas MD Anderson Cancer Center
						
					
					
				
					
						 and 
						
						
							Larry D. Anderson Jr., MD, PhD, UT Southwestern Medical Center
						
					
					
				
			
 
			
			Disclosures:
			
			
				
			
				
			
			Patel: AbbVie; Arcellx, AstraZeneca; Bristol Myers Squibb/Celgene Corporation; Caribou Science; Cellectis; Curio Bioscience; Genentech; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; Precision BioSciences: Consultancy; AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb/Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.: Research Funding; Takeda: Consultancy. Anderson: Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Beigene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Cellectar: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Prothena: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. 
			 
		This session focuses on clinical trial updates and real world data for Hematologic Malignancies including multiple myeloma, B-cell ALL and B-cell lymphomas.
		
		
	
	4:30 PM
	
	
4:45 PM
	
	
5:00 PM
	
	
5:15 PM
	
	
5:30 PM
	
	
5:45 PM
	
	
	
	
	See more of: Oral and Poster Abstracts
	
	
	
	
	*signifies non-member of ASH
					
	
	
 denotes an abstract that is clinically relevant.
 denotes that this is a recommended PHD Trainee Session.